Another remarkable change refers to the recognition of particular clinicobiological entities associated with adverse risk, AML with a TP53 mutation and the renamed AML with myelodysplasia-related gene mutations (ICC 2022)/AML myelodysplasia-related (WHO 2022), which harbor specific cytogenetic and molecular alterations beyond those previously considered ASXL1 and RUNX1 (Table 2). This evidence concerns the gene TP53 and acute myeloid leukemia.